Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Myeloproliferative Neoplasms

The ipsogen JAK2 RGQ PCR Kit  received clearance from the U.S. FDA for additional use in the diagnosis of all myeloproliferative neoplasms.
New research published in Annals of Internal Medicine shows that the rate of arterial and venous thrombosis was significant in patients with myeloproliferative neoplasms (MPNs).
New research published in Annals of Internal Medicine shows that the rate of arterial and venous thrombosis was significant in patients with myeloproliferative neoplasms (MPNs).
Emmaus Life Sciences has announced that Endari, a medication developed to reduce acute complications in patients with sickle cell disease, is now available by prescription in the United States.
UT Health Cancer Center Director Ruben Mesa, MD, explains the anemia that can sometimes come with MPN-associated myelofibrosis, and the pertinent data presented at ASH 2017.
Data presented at the 59th Annual American Society of Hematology Meeting and Exposition concludes that Sotatercept is effective in patients with MPN-associated myelofibrosis and anemia.
The first patients have been dosed in a Phase 1/2 clinical trial of IMG-7289 for the treatment of myelofibrosis (MF), according to Imago BioSciences.
A Phase 1 clinical study testing CAR T-cell therapy, UCART123,to treat blastic plasmacytoid dendritic cell neoplasm at the MD Anderson Cancer Center has begun.
In this video clip, Srdan Verstovsek, MD PhD; and Jamile M. Shammo, MD discuss the presentation of polycythemia vera and NCCN Guidelines for myeloproliferative neoplasms
The FDA has approved Beckman Coulter's ClearLLab Reagents to help diagnose numerous rare blood cancers, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.